The Competitive N-Methyl-d-aspartate Receptor Antagonist (-)-6-Phosphonomethyl-deca-hydroisoquinoline-3-carboxylic Acid (LY235959) Potentiates the Antinociceptive Effects of Opioids That Vary in Efficacy at the μ-Opioid Receptor
Open Access
- 1 November 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 307 (2) , 785-792
Abstract
(-)-6-Phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) is a competitive N-methyl-d-aspartate receptor antagonist shown to prevent the development of tolerance to the antinociceptive effects of morphine in rodents. Although administration of LY235959 alone generally does not produce antinociception, LY235959 potentiates the antinociceptive effects of morphine in squirrel monkeys. The present study was designed to determine whether LY235959 would potentiate the acute antinociceptive effects of morphine as well those of the opioid receptor agonists l-methadone, levorphanol, butorphanol, and buprenorphine. A squirrel monkey titration procedure was used in which shock (delivered to the tail) increased in intensity every 15 s (0.01-2.0 mA) in 30 increments. Five lever presses during any given 15-s shock period (fixed ratio 5) produced a 15-s shock-free period after which shock resumed at the next lower intensity. Morphine (0.3-3.0 mg/kg i.m.), l-methadone (0.1-0.56 mg/kg i.m.), levorphanol (0.1-1.0 mg/kg i.m.), butorphanol (1.0-10 mg/kg i.m.), and buprenorphine (0.01-0.03 mg/kg i.m.), but not LY235959 (0.1-1.0 mg/kg i.m.), dose and time dependently increased the intensity below which monkeys maintained shock 50% of the time (median shock level, MSL). LY235959 dose dependently potentiated the effect of each opioid agonist on MSL when concurrently administered to monkeys. Although LY235959 potentiated the antinociceptive effect of each opioid examined in a statistically significant manner, LY235959 seemed more potent and effective when combined with higher efficacy opioids. The present data suggest that the N-methyl-d-aspartate antagonist, LY235959, can potentiate the antinociceptive effects of a range of opioid receptor agonists independently of nonspecific motor effects.Keywords
This publication has 37 references indexed in Scilit:
- Use of Irreversible Antagonists to Determine the Relative Efficacy of μ-Opioids in a Pigeon Drug Discrimination Procedure: Comparison of β-Funaltrexamine and ClocinnamoxThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Dextromethorphan and ketamine potentiate the antinociceptive effects of μ- but not δ- or κ-opioid agonists in a mouse model of acute painPharmacology Biochemistry and Behavior, 2002
- Dextromethorphan Potentiates the Antinociceptive Effects of Morphine and the δ-Opioid Agonist SNC80 in Squirrel MonkeysThe Journal of Pharmacology and Experimental Therapeutics, 2002
- An Examination of the Interactions Between the Antinociceptive Effects of Morphine and Various [micro sign]-OpioidsAnesthesia & Analgesia, 1999
- Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective μ or δ opioid agonists in micePain, 1996
- Anxiolytic-like and antinociceptive effects of MK-801 accompanied by sedation and ataxia in primatesPharmacology Biochemistry and Behavior, 1993
- Abuse liability studies of opioid agonist-antagonists in humansDrug and Alcohol Dependence, 1991
- Opioid Agonist-Antagonist Drugs in Acute and Chronic Pain StatesDrugs, 1991
- Inhibition of Morphine Tolerance and Dependence by the NMDA Receptor Antagonist MK-801Science, 1991
- Differences in Efficacies Between Morphine and Methadone Demonstrated in the Guinea Pig Ileum: A Possible Explanation for Previous Observations on Incomplete Opioid Cross‐ToleranceBasic & Clinical Pharmacology & Toxicology, 1989